Harvard Bioscience, Inc.
General ticker "HBIO" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $35.7M (TTM average)
Harvard Bioscience, Inc. follows the US Stock Market performance with the rate: 33.3%.
Estimated limits based on current volatility of 3.3%: low 0.57$, high 0.61$
Factors to consider:
- Earnings expected soon, date: 2026-03-12 bmo
- Total employees count: 355 (-14.7%) as of 2024
- China accounted for 14.1% of revenue in the fiscal year ended 2024-12-31
- US accounted for 44.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Technological obsolescence, Dependence on pharmaceutical and biotech industries, Geopolitical risks, Cybersecurity threats
- Current price 69.1% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.53$, 3.61$]
- 2025-12-31 to 2026-12-31 estimated range: [1.85$, 4.11$]
Financial Metrics affecting the HBIO estimates:
- Positive: with PPE of 69.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: 42.68 < Shareholder equity ratio, % of 50.01 <= 64.29
- Negative: negative Net income
- Positive: -0.01 < Industry operating cash flow per share per price (median), % of 0.78
Short-term HBIO quotes
Long-term HBIO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $113.33MM | $112.25MM | $94.14MM |
| Operating Expenses | $120.27MM | $110.36MM | $100.35MM |
| Operating Income | $-6.93MM | $1.89MM | $-6.21MM |
| Non-Operating Income | $-2.25MM | $-4.45MM | $-5.45MM |
| Interest Expense | $2.55MM | $3.59MM | $3.21MM |
| R&D Expense | $12.33MM | $11.76MM | $10.41MM |
| Income(Loss) | $-9.18MM | $-2.56MM | $-11.66MM |
| Taxes | $0.34MM | $0.86MM | $0.74MM |
| Profit(Loss)* | $-9.52MM | $-3.42MM | $-12.40MM |
| Stockholders Equity | $72.22MM | $73.07MM | $63.34MM |
| Inventory | $26.44MM | $24.72MM | $23.25MM |
| Assets | $145.36MM | $137.37MM | $126.64MM |
| Operating Cash Flow | $1.15MM | $14.03MM | $1.44MM |
| Capital expenditure | $1.59MM | $2.31MM | $3.26MM |
| Investing Cash Flow | $-1.59MM | $-1.80MM | $-1.34MM |
| Financing Cash Flow | $-2.84MM | $-12.13MM | $-0.13MM |
| Earnings Per Share** | $-0.23 | $-0.08 | $-0.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.